Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Graefes Arch Clin Exp Ophthalmol. 2014 Aug 5;252(11):1755–1762. doi: 10.1007/s00417-014-2749-5

Fig. 4.

Fig. 4

sVEGFR-3 treatment prolongs corneal allograft survival. BALB/c recipient mice received C57BL/6 corneal grafts and were treated intra-peritoneally with sVEGFR-3 or PBS starting the day of transplantation up to 8 weeks once every other day. Graft survival was followed biomicroscopically and a Kaplan–Meier curve was plotted to compare the survival in the two study groups. The log-rank test was used for statistical analysis. sVEGFR-3-treated mice showed a survival rate of 87.5 % (n=16) compared to a 50 % survival rate in PBS-treated mice (n= 10)